Cohort . | Number of subjectsa . | Frequencyb . | βb . | SE . | P-value . |
---|---|---|---|---|---|
TwinsUK (discovery study) | 2772 | 0.55 | 0.56 | 0.101 | 3.48 × 10−8 |
BATS | 1152 | 0.53 | 0.147 | 0.13 | 0.2602 |
BMES | 1667 | 0.55 | 0.0384 | 0.099 | 0.6994 |
ERF | 2589 | 0.57 | 0.064 | 0.089 | 0.476 |
Framingham | 2455 | 0.54 | 0.090 | 0.091 | 0.327 |
GHS1 | 2727 | 0.56 | 0.136 | 0.078 | 0.081 |
GHS2 | 1130 | 0.55 | −0.020 | 0.113 | 0.858 |
ORCADES | 474 | 0.54 | 0.358 | 0.184 | 0.051 |
RSIII | 2034 | 0.57 | 0.057 | 0.092 | 0.537 |
RSII | 2116 | 0.56 | 0.066 | 0.094 | 0.483 |
RSI | 5782 | 0.57 | 0.101 | 0.062 | 0.106 |
Southampton | 166 | 0.55 | 0.042 | 0.492 | 0.932 |
TEST | 663 | 0.53 | 0.010 | 0.194 | 0.960 |
Cohort . | Number of subjectsa . | Frequencyb . | βb . | SE . | P-value . |
---|---|---|---|---|---|
TwinsUK (discovery study) | 2772 | 0.55 | 0.56 | 0.101 | 3.48 × 10−8 |
BATS | 1152 | 0.53 | 0.147 | 0.13 | 0.2602 |
BMES | 1667 | 0.55 | 0.0384 | 0.099 | 0.6994 |
ERF | 2589 | 0.57 | 0.064 | 0.089 | 0.476 |
Framingham | 2455 | 0.54 | 0.090 | 0.091 | 0.327 |
GHS1 | 2727 | 0.56 | 0.136 | 0.078 | 0.081 |
GHS2 | 1130 | 0.55 | −0.020 | 0.113 | 0.858 |
ORCADES | 474 | 0.54 | 0.358 | 0.184 | 0.051 |
RSIII | 2034 | 0.57 | 0.057 | 0.092 | 0.537 |
RSII | 2116 | 0.56 | 0.066 | 0.094 | 0.483 |
RSI | 5782 | 0.57 | 0.101 | 0.062 | 0.106 |
Southampton | 166 | 0.55 | 0.042 | 0.492 | 0.932 |
TEST | 663 | 0.53 | 0.010 | 0.194 | 0.960 |
BATS, Brisbane Adolescent Twin Study; BMES, Blue Mountains Eye Study; ERF, Erasmus Rucphen Family Study; GHS, Guttenberg Health Study; ORCADES, Orkney Complex Disease Study; RS, Rotterdam Study; TEST, Tasmanian Eye Study of Twins; SE, dtandard error.
aNumber of subjects refers to those with genotype information for rs2286885.
bFrequency and beta refer to the frequency and the effect size respectively for the A allele of rs2286885.
Cohort . | Number of subjectsa . | Frequencyb . | βb . | SE . | P-value . |
---|---|---|---|---|---|
TwinsUK (discovery study) | 2772 | 0.55 | 0.56 | 0.101 | 3.48 × 10−8 |
BATS | 1152 | 0.53 | 0.147 | 0.13 | 0.2602 |
BMES | 1667 | 0.55 | 0.0384 | 0.099 | 0.6994 |
ERF | 2589 | 0.57 | 0.064 | 0.089 | 0.476 |
Framingham | 2455 | 0.54 | 0.090 | 0.091 | 0.327 |
GHS1 | 2727 | 0.56 | 0.136 | 0.078 | 0.081 |
GHS2 | 1130 | 0.55 | −0.020 | 0.113 | 0.858 |
ORCADES | 474 | 0.54 | 0.358 | 0.184 | 0.051 |
RSIII | 2034 | 0.57 | 0.057 | 0.092 | 0.537 |
RSII | 2116 | 0.56 | 0.066 | 0.094 | 0.483 |
RSI | 5782 | 0.57 | 0.101 | 0.062 | 0.106 |
Southampton | 166 | 0.55 | 0.042 | 0.492 | 0.932 |
TEST | 663 | 0.53 | 0.010 | 0.194 | 0.960 |
Cohort . | Number of subjectsa . | Frequencyb . | βb . | SE . | P-value . |
---|---|---|---|---|---|
TwinsUK (discovery study) | 2772 | 0.55 | 0.56 | 0.101 | 3.48 × 10−8 |
BATS | 1152 | 0.53 | 0.147 | 0.13 | 0.2602 |
BMES | 1667 | 0.55 | 0.0384 | 0.099 | 0.6994 |
ERF | 2589 | 0.57 | 0.064 | 0.089 | 0.476 |
Framingham | 2455 | 0.54 | 0.090 | 0.091 | 0.327 |
GHS1 | 2727 | 0.56 | 0.136 | 0.078 | 0.081 |
GHS2 | 1130 | 0.55 | −0.020 | 0.113 | 0.858 |
ORCADES | 474 | 0.54 | 0.358 | 0.184 | 0.051 |
RSIII | 2034 | 0.57 | 0.057 | 0.092 | 0.537 |
RSII | 2116 | 0.56 | 0.066 | 0.094 | 0.483 |
RSI | 5782 | 0.57 | 0.101 | 0.062 | 0.106 |
Southampton | 166 | 0.55 | 0.042 | 0.492 | 0.932 |
TEST | 663 | 0.53 | 0.010 | 0.194 | 0.960 |
BATS, Brisbane Adolescent Twin Study; BMES, Blue Mountains Eye Study; ERF, Erasmus Rucphen Family Study; GHS, Guttenberg Health Study; ORCADES, Orkney Complex Disease Study; RS, Rotterdam Study; TEST, Tasmanian Eye Study of Twins; SE, dtandard error.
aNumber of subjects refers to those with genotype information for rs2286885.
bFrequency and beta refer to the frequency and the effect size respectively for the A allele of rs2286885.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.